Compare Synopsys, Inc. (SNPS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Synopsys, Inc. trades at $388.85 (market cap $72.47B), while State Street SPDR S&P Biotech ETF trades at $154.32. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| SNPS | XBI | |
|---|---|---|
Market Cap | $72.47B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $645.59 | $164.28 |
52-Week Low | $378.46 | $85.16 |
Enterprise Value | $80.82B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $388.84, up 1.19% on the day, with a bearish technical signal despite recent earnings beats. The stock faces headwinds from semiconductor sector volatility but maintains strong analyst support with an 82.76% buy rating. Recent news highlights the company's strategic pivot toward AI design tools and margin expansion following its Ansys integration, positioning it as a key enabler in the chip design ecosystem despite near-term price pressure.
Outlook remains positive long-term due to SNPS's dominant EDA market position and AI-driven growth opportunities, though investors face risks from cyclical semiconductor demand and integration execution. The consensus price target of $559.50 implies significant upside if the company delivers on its AI strategy and margin improvements.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
